Modulation of toll-like receptor function has therapeutic potential in autoimmune disease.
Clanchy
Felix I L
FI
Kennedy Institute of Rheumatology Division, Imperial College of Science, Technology and Medicine, Faculty of Medicine, Hammersmith, London, UK. f.clanchy@imperial.ac.uk
Sacre
Sandra M
SM
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008024:Ligands; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000276:immunology; D058990:Molecular Targeted Therapy; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology; D015398:Signal Transduction / Q000187:drug effects; D051193:Toll-Like Receptors / Q000187:drug effects* / Q000276:immunology
D000893:Anti-Inflammatory Agents; D008024:Ligands; D051193:Toll-Like Receptors